Başkent Üniversitesi Yayınları
Permanent URI for this communityhttps://hdl.handle.net/11727/13092
Browse
16 results
Search Results
Item Determinants of Coronary Artery Disease in Liver Transplant Candidates(Başkent Üniversitesi, 2010-06) Muderrisoglu, Haldun; Haberal, Mehmet; Aydinalp, Alp; Atar, Ilyas; Bal, Ugur; Aktas, Ayse; Ertan, Cagtay; Atar, Asli; Yildirir, Aylin; Ozin, BulentObjectives: The potential for perioperative and late cardiovascular complications in liver transplant candidates makes careful preoperative risk assessment imperative. We sought to identify the determinants of coronary artery disease in liver transplant candidates. Materials and Methods: Liver transplant candidates with end-stage liver disease who were more than 40 years old and undergoing coronary angiography were retrospectively included in this study. Patients with known coronary heart disease or valvular heart disease were excluded. Symptoms, coronary artery disease risk factors, blood tests, electrocardiogram, echocardiography, treadmill stress test, myocardial perfusion scintigraphy, and coronary angiography results were recorded. A multivariable logistic regression model was used to assess the independent predictors of coronary artery disease. Results: A total of 139 patients (mean age, 52 ± 8; 110 male [79%]) were included in the analysis. Coronary angiography revealed that 13 patients (9.4%) had coronary artery disease. The frequency of diabetes mellitus, stable angina symptoms, positive smoking status, presence of 2 or more risk factors for coronary artery disease, and mean low-density lipoprotein cholesterol levels were significantly higher in patients with coronary artery disease than in patients without coronary artery disease. The electrocardiogram, echocardiography, and noninvasive stress test results were not valuable tools in liver transplant candidates for the diagnosis of coronary artery disease. In multivariate analysis, typical angina symptoms and low-density lipoproteins cholesterol levels appeared to be independent factors that were predictive of coronary artery disease. Conclusions: Typical anginal symptoms and low-density lipoprotein cholesterol levels seem to be the best predictors of coronary artery disease in liver transplant candidates.Item Risk Factors for Biliary Complications After Living-Donor Liver Transplant: A Single-Center Experience(Başkent Üniversitesi, 2008-06) Alawi, Khalil; Sebayel, Mohammed; Abdo, Ayman; Al-Hamoudi, Waleed; Al-Bahili, Hamad; Al-Sofayan, Mohamed; Al-Saghier, Mohamed; Allam, Naglaa; Medhat, Yaser; Khalaf, HatemObjectives: Biliary complications remain a major concern in living-donor liver transplant. They can lead to patient and graft loss. In this study, we retrospectively analyzed patients’ records to identify factors that increase the frequency of biliary complications in living-donor liver transplant with an aim toward decreasing this frequency. Materials and Methods: We performed 53 living-donor liver transplants between November 2002 and September 2007. Five cases were excluded because of graft or patient loss within 2 weeks resulting in 48 cases available for analysis. The effect of the following variables on the frequency of biliary complications was analyzed: recipient age, liver lobe used, number of graft bile ducts, number of biliary anastomoses, type of biliary anastomosis, and bile duct diameter 4 mm or smaller. Results: Biliary complications were seen in 14 cases (29.1%). These included 9 biliary strictures, 3 bile leaks, and 2 bile leaks eventually healing as biliary strictures. The presence of more than 1 graft bile duct increased the frequency of biliary complications (P = .03). The other variables did not have a statistically significant effect on the frequency of biliary complications. Conclusions: The rate of complications in our experience is comparable to that already published. The presence of more than 1 bile duct in the graft is a risk factor for biliary complications in living-donor liver transplant. A review of the data suggests additional risk factors.Item Sinus Bradycardia Associated With Daclizumab in Liver Transplant Recipients: Report of 3 Cases(Başkent Üniversitesi, 2008-12) Bassily-Marcus, Adel; Benjamin, Ernest; Manasia, Anthony; Oropello, John; Murgolo, Victor; Leibowitz, Andrew; Kohli-Seth, RoopaDaclizumab is a commonly used immunosuppressive agent for prophylaxis of solid organ rejection. Although rare, the cardiovascular adverse effects of daclizumab include sinus tachycardia, hypotension, and hypertension. Here, we report 3 patients who developed significant and prolonged sinus bradycardia after receiving daclizumab following orthotopic liver transplant. Daclizumab should be considered a possible cause of bradycardia following its administration in orthotopic liver transplant.Item Renal Allograft Abscesses Following Transplant: Case Report and Literature Review(Başkent Üniversitesi, 2007-12) Shoja, Mohammadali M.; Varshochi, Mojtaba; Tubbs, R. Shane; Etemadi, Jalal; Ardalan, Mohamad R.Intrarenal and perinephric abscess formations are infrequent infectious complications in kidney allograft recipients. A 37-year-old man who was a victim of mustard gas chemical weapons from the Iran-Iraq war received a live-donor kidney transplant for end-stage renal disease. The posttransplant course was complicated by clinical rejection, which subsided after a 2-week infusion of antithymocyte globulin. One month subsequent to this, the patient presented with renal allograft dysfunction and multiple intrarenal abscesses. Culture from the purulent aspirate of a percutaneously drained renal abscess revealed multidrug-resistant Pseudomonas aeruginosa. A concomitant acute cytomegalovirus infection was detected based on positive serologic tests. Treatment with intravenous meropenem (3 g/day for 3 weeks) and oral ciprofloxacin was begun, which resulted in the complete resolution of the intrarenal abscesses. To our knowledge, this report represents the first description of pseudomonal renal abscesses in a renal transplant recipient. A review of the relevant literature is presented.Item Unusual Presentation of Recurrent Hepatocellular Carcinoma as Obstructive Jaundice 15 Years after Liver Transplant(Başkent Üniversitesi, 2007-12) Camci, Cemalettin; Jabbour, Nicolas; Sharma, Sharad; Kohli, Vivek; Gurakar, AhmetHepatocellular carcinoma recurrence is a known limitation of liver transplant. Recurrence rates have been reported in 10% to 60% of patients within an average of 1 to 2 years following liver transplant. We report a case of recurrent hepatocellular carcinoma 15 years after orthotopic liver transplant, presenting initially as obstructive bile duct compression as detected by cholangiogram. Laparotomy revealed hepatocellular carcinoma invading the common bile duct without any mass in the liver parenchyma. The main focus of the case is the endoscopic retrograde cholangiopancreatography image, which is unique in the setting of liver disease following liver transplant.Item Life in Death: an Overview of Solid Organ Transplant in Shiraz, Iran(Başkent Üniversitesi, 2007-12) Mehdizadeh, Alireza; Fazelzadeh, AfsoonAdvances in organ preservation, immunosuppression, and surgical procedures have resulted in improved outcomes and survival rates. However, regarding organ transplant in different communities, these advances raise major ethical, policy, and religious issues. Transplant progress in Iran, in relation to the rest of the world, has been slow at times and quick during others. Between 1988 and 1993, there was a rapid surge in experiments with tissue transplant in Iran, and the Shiraz Organ Transplantation Center, established in 1988, rose to become a pioneer of the most significant improvements, a leading center for organ transplant, and the only center for liver transplant in Iran. In this article, we review milestones in the development of a successful organ transplant program and implementation of legislation in Iran. The Shiraz model of transplant is a new program that attempts to overcome the problems of organ shortage. We provide a description of the Iranian model of transplant and its restrictions and examine the most promising future trends in this exciting field.Item Methylenetetrahydrofolate Reductase C677T Genotypes and Clinical Outcome Following Hematopoietic Cell Transplant(Başkent Üniversitesi, 2007-12) Azarpira, Negar; Geramizadeh, Bita; Darai, Masumeh; Aghdaie, Mahdokht Hossein; Ramzi, ManiObjective: Methotrexate may be used as a prophylactic agent against graft-versus-host disease in hematopoietic cell transplant. The drug exerts its effect on folate metabolism; 5,10-methylenetetrahydrofolate reductase is a critical enzyme involved in this cycle and is related to the toxicity of methotrexate. Methods: We examined the association of a single nucleotide polymorphism at position 677 in the 5,10-methylenetetrahydrofolate reductase gene and the clinical outcomes of patients treated with allogeneic hematopoietic cell transplant. Genotyping of 5,10-methylenetetrahydrofolate reductase was performed by polymerase chain reaction-restriction fragment length polymorphism on 30 patients receiving hematopoietic cell transplant and their HLA-matched related donors. Patients were given a short course of methotrexate as prophylaxis to prevent graft-versus-host disease. Results: Donors and recipients who carried a 677T allele showed mildly higher total bilirubin, aspartic transaminase, and alanine transaminase levels, but these increases above the normal values were not statistically significant (P > .05). The platelet recovery to 20 000/µL and granulocyte recovery to 500/µL were slower for patients who carried a 677T allele, but these correlations also were not statistically significant. The 5,10-methylenetetrahydrofolate reductase genotypes of neither the donors nor the recipients had any effect on the incidence of acute graft-versus-host disease. Conclusions: No association was observed between the C677T polymorphism and the outcome parameters for any of the different genotypes studied here. Additional studies with larger samples are necessary to further elucidate the influence of 5,10-methylenetetrahydrofolate reductase genotyping on clinical outcomes of patients treated with hematopoietic cell transplant who receive methotrexate.Item Steroid Avoidance in Renal Transplant Patients Maintained on a Cyclosporine-based Protocol(2007-12) Ko, Tina Y; Julie A Haddy,; Sureshkumar, Kalathil K.; Breckenridge, Molly; Patel, Satish; Marcus, Richard J.; Sandroni, Stephen E.; McGill, Rita L.; Carpenter, Barbara J.; Nghiem, Dai D.Objective: The aim of this study was to analyze the effect of steroid avoidance, as compared with our pre-existing protocol that contained steroids, on renal allograft and patient survival. Secondary outcomes included body weight, diabetes, hyperlipidemia, and infection. Materials and Methods: This retrospective chart review of the results of steroid avoidance was performed in 169 patients who had undergone renal transplant between January 2000 and March 2002 and had received an immunosuppression regimen of cyclosporine, mycophenolate mofetil, and prednisone; and 148 patients who had undergone transplant between November 2002 and November 2004 who had received induction immunosuppression with a steroid taper by postoperative day 4 and were maintained on cyclosporine and mycophenolate mofetil. Results: One-year allograft survival rates, rejection-free graft survival rates, and patient survival rates were 88%, 76%, and 97%, respectively, in the steroid-maintenance group compared with 90%, 74%, and 96%, respectively, in the steroid-avoidance group (P = NS). No differences were detected in multiple secondary variables related to the metabolic effects of steroid therapy. Conclusions: These data suggest that steroid avoidance can be performed safely and effectively in patients on a cyclosporine-based protocol of immunosuppression. Longer follow-ups are suggested to determine the effects of limited steroid exposure on the metabolic profiles of patients.Item Successful Living-Donor Liver Transplantation and Retransplantation with Cavoportal Hemitransposition: A Case Report(Başkent Üniversitesi, 2006-12) Ozden, Ilgin; Suoglu, Ozlem Durmaz; Aydogan, Aysen; Bilge, Orhan; Yavru, Aysen; Sokucu, Semra; Acarli, KorayAn 11-month-old female infant underwent living-donor liver transplantation for secondary biliary cirrhosis 8 months after Kasai operation. The portal vein was hypoplastic, and its diameter was only 4 mm at the level of the splenomesenteric confluence. End-to-end anastomosis of the recipient suprarenal vena cava to the graft portal vein (a left lateral section from the patient’s mother) was performed. An end-to-side portocaval shunt with the recipient portal vein was constructed to mitigate portal hypertension. The early postoperative course was relatively uneventful. However, persistent hepatitis caused by infection with Cytomegalovirus and chronic rejection resulted in progressive hepatic dysfunction. Nine months after the initial operation, a living-donor retransplantation (a left lateral section from the patient’s grandmother) was performed. One month after retransplantation, severe acute rejection that eventually required OKT3 treatment developed. The patient was in excellent health until 4 months after retransplantation, when another acute rejection episode (for which she was successfully treated) developed. Cavoportal hemitransposition should be included in the armamentarium of the transplant surgeon for the management of extensive portal system thrombosis and portal vein hypoplasia. An additional shunt may be useful in mitigating portal hypertension.Item Quiescent Interplay Between Inducible Nitric Oxide Synthase and Tumor Necrosis Factor-α: Influence on Transplant Graft Vasculopathy in Renal Allograft Dysfunction(Başkent Üniversitesi, 2006-06) Elahi, Maqsood M.; Matata, Bashir M.; Hakim, Nadey S.A healthy endothelium is essential for vascular homeostasis, and preservation of endothelial cell function is critical for maintaining transplant allograft function. Damage to the microvascular endothelial cells is now regarded as a characteristic feature of acute vascular rejection, an important predictor of graft loss. It is also linked with transplant vasculopathy, often associated with chronic allograft nephropathy. Large bursts of nitric oxide in infiltrating monocytes/macrophages modulated by inducible nitric oxide synthase are considered pivotal in driving this mechanism. Indeed, it has been shown recently that increased circulating levels of tumor necrosis factor-α in the rejecting kidneys are largely responsible for triggering inducible nitric oxide synthase expression. This in turn suggests that several structural and functional features of graft rejection could be mediated by tumor necrosis factor-α. Despite the large body of evidence that supports immunologic involvement, knowledge concerning the cellular and biochemical mechanisms for nephritic cell dysfunction and death is incomplete. The role of tumor necrosis factor-α in mediating pathophysiological activity of inducible nitric oxide synthase during transplant vasculopathy remains contentious. Here, we discuss the effect of inducible nitric oxide synthase and tumor necrosis factor-α interaction on progressive damage to glomerular and vascular structures during renal allograft rejection. Selective inhibition of inducible nitrous oxide synthase and tumor necrosis factor-a as a potential therapy for ameliorating endothelial dysfunction and transplant graft vasculopathy is also discussed.